Managing Rheumatologic Diseases in Pregnancy

BY BRUCE JANCIN
FROM A SYMPOSIUM SPONSORED BY THE AMERICAN COLLEGE OF RHEUMATOLOGY

SNOWMASS, COLO. – Corticosteroids can be thought of as the ‘go-to’ drugs for the management of rheumatologic disorders in pregnancy.

“Corticosteroids have been my ace in the hole in treating many patients during pregnancy. They’re potent immunosuppressives that can get you out of a lot of trouble. And although they can have side effects, if used judiciously they are a reasonable treatment choice,” Dr. Bonnie L. Bermas stressed at the symposium.

Reassuringly, transplant registries comprising many tens of thousands of organ recipients have shown no increased rate of congenital anomalies with the use of corticosteroids in pregnancy.

However, an influential University of Toronto meta-analysis has concluded that “although prednisone does not represent a major teratogenic risk in humans at therapeutic doses, it does increase by an order of 3.4-fold the risk of oral cleft” (Teratology 2000;62:385-92).

“What this translates to in your practice is, the cleft palate incidence increases from 1 in 1,000 in the general population to about 1 in 300 live births exposed to steroids in utero. That’s how I counsel my patients who need to be on corticosteroids in the first trimester,” said Dr. Bermas, clinical director of the lupus center at Brigham and Women’s Hospital in Boston.

After 12-14 weeks’ gestation, however, the palate is formed. And although steroids are no longer associated with an increased risk for cleft palate after that point in gestation, other risks remain. These include gestational diabetes, gestational hypertension, osteoporosis in the mother, premature rupture of the membranes, and small-for-gestational-age infants.

Prednisone and methylprednisolone—the steroid rheumatologists utilize most often—don’t cross the placenta efficiently, and hence are much less likely to cause fetal adverse effects than are dexamethasone or betamethasone.

Steroids that are administered to the mother make their way into breast milk only in low concentrations. If she’s on less than 20 mg/day of prednisone, she can breastfeed normally. For women on higher doses, Dr. Bermas advises pumping and discarding the breast milk for the first 4 hours after a dose is taken.

Dr. Bermas emphasized that the key to successful treatment of rheumatologic disorders during pregnancy is a clear-eyed assessment of and accommodation to the patient’s tolerance for risk—and the physician’s, as well.

“There are some women who do not drink caffeinated beverages or take any medications, not even a TYLENOL, and who will eat only organic foods while pregnant. There are others who are willing to tolerate some risk during pregnancy. And as clinicians, we have our own risk tolerances, too. For example, azathioprine is a medication that I feel comfortable using during pregnancy, but I have colleagues who won’t because they wouldn’t be able to sleep at night,” she explained.

The reason she prescribes azathioprine during pregnancy—despite its category D rating from the Food and Drug Administration, indicating “positive evidence of risk”—is that there’s an enormous transplant literature showing no increase in congenital anomalies with in utero exposure to this drug.

Mycophenolate mofetil (CellCept) also has a category D rating. But unlike azathioprine, mycophenolate mofetil has no extensive and reassuring transplant literature. As a result, Dr. Bermas said that she avoids it in pregnancy and nursing.

Other rheumatologic medications to avoid in pregnancy are methotrexate, penicillamine, 6-mercaptopurine, and...
In treating your postmenopausal osteoporosis patients at high risk for fracture, help . . .

BE A FORCE AGAINST FRACTURE

Prolia™ targets and binds to RANK Ligand, inhibiting osteoclast formation, function, and survival

Prolia™ significantly reduced fracture risk at key sites* in a phase 3 trial1,2

Vertebral Fracture†

Hip Fracture

Nonvertebral Fracture‡

68%**

ARR 1.4%

40%**

p = 0.01

ARR 0.3%

20%**

p < 0.001

ARR 1.5%

N = 7808

3-year, placebo-controlled trial.

Prolia™ is a subcutaneous injection administered every 6 months in your office.

Please see Brief Summary of Prescribing Information on the following page.

Prolia™ Postmarketing Active Safety Surveillance Program: The Prolia™ Postmarketing Active Safety Surveillance Program is available to collect information from prescribers on specific adverse events. Please go to www.proliasafety.com or call 1-800-777-6436 for more information about this program.

† Key sites: vertebral, hip, and nonvertebral fractures.
‡ Includes 79% patients with a baseline and at least one post-baseline radiograph.
§ Composite measurement excluding pathological fractures and those associated with severe trauma, fractures of the vertebral, skull, face, mandible, metacarpals, fingers, and toes.

©2010 Amgen Inc  All rights reserved.


For more information, visit www.ProliaHCP.com

Be performed by the prescriber prior to initiation of Prolia™. A dental examination with appropriate preventive dentistry should be considered prior to treatment in patients with risk factors for ONJ. Good oral hygiene practices should be maintained during treatment with Prolia™.

For patients requiring invasive dental procedures, clinical judgment should guide the management plan of each patient. Patients who are suspected of having or who develop ONJ should receive care by a dentist or an oral surgeon. Extensive dental surgery to treat ONJ may be considered based on individual benefit-risk assessment.

Suppression of Bone Turnover: Prolia™ resulted in significant suppression of bone remodeling as evidenced by markers of bone turnover and bone histomorphometry. The significance of these findings and the effect of long-term treatment are unknown. Monitor patients for consequences, including ONJ, atypical fractures, and delayed fracture healing.

Adverse Reactions: The most common adverse reactions (> 5% and more common than placebo) are back pain, pain in extremity, musculoskeletal pain, hypercholesterolemia, and cystitis. Pancreatitis has been reported with Prolia™.

The overall incidence of new malignancies was 4.3% in the placebo and 4.8% in the Prolia™ groups. A causal relationship to drug exposure has not been established. Denosumab is a human monoclonal antibody. As with all therapeutic proteins, there is potential for immunogenicity.